Evidence map›Paper›PMID 38915323›Full record

ArticleRSC advances2024

Synthesis and biological research of new imidazolone-sulphonamide-pyrimidine hybrids as potential EGFR-TK inhibitors and apoptosis-inducing agents.

Dalal Nasser Binjawhar, Hanadi A Katouah, Najla A Alshaye, Jawaher Alharthi, Ghadi Alsharif, Fahmy G Elsaid, Eman Fayad, Ali H Abu Almaaty

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dalal Nasser BinjawharDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University P.O. Box 84428 Riyadh 11671 Saudi Arabia.
Hanadi A KatouahChemistry Department, College of Science, Umm Al-Qura University 21955 Makkah Saudi Arabia.
Najla A AlshayeDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University P.O. Box 84428 Riyadh 11671 Saudi Arabia.
Jawaher AlharthiDepartment of Biotechnology, College of Sciences, Taif University P.O. Box 11099 Taif 21944 Saudi Arabia.
Ghadi AlsharifDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences P.O.Box 9515 Jeddah 21423 Saudi Arabia.
Fahmy G ElsaidDepartment of Biology, College of Science, King Khalid University PO Box 960 Abha Asir 61421 Saudi Arabia.
Eman FayadDepartment of Biotechnology, College of Sciences, Taif University P.O. Box 11099 Taif 21944 Saudi Arabia.
Ali H Abu AlmaatyZoology Department, Faculty of Science, Port Said University Port Said 42526 Egypt aliabuelmaaty8@gmail.com.ORCID https://orcid.org/0009-0002-6225-4308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of new effective EGFR-targeted antitumor agents is needed because of their clinical significance. A new series of imidazolone-sulphonamide-pyrimidine hybrids was designed and synthesized as modified analogs of some reported EGFR inhibitors. The cytotoxic activity of all the synthesized hybrids was investigated against the breast MCF-7 cancerous cell line using doxorubicin (Dox) as a positive control. 4-(Furan-2-ylmethylene)imidazolone-sulphonamide-pyrimidine 6b had the best potent activity against MCF-7 cells with IC

Identifiers

PMID38915323
PMCPMC11194663

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.